Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Latest Biotechnology and Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics, Inc. Stock News

As of September 2, 2026, Arrowhead Pharmaceuticals, Inc. had a $12.1 billion market capitalization, compared to the Biotechnology median of $288.9 million. Arrowhead Pharmaceuticals, Inc.’s stock is up 30.3% in 2026, down 2.4% in the previous five trading days and up 232.44% in the past year.

Currently, Arrowhead Pharmaceuticals, Inc. does not have a price-earnings ratio. Arrowhead Pharmaceuticals, Inc.’s trailing 12-month revenue is $669.5 million with a -47.8% net profit margin. Year-over-year quarterly sales growth most recently was 170.9%. Analysts expect adjusted earnings to reach $-3.607 per share for the current fiscal year. Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.

As of September 2, 2026, Halozyme Therapeutics, Inc. had a $12.4 billion market cap, putting it in the 80th percentile of all stocks. Halozyme Therapeutics, Inc.’s stock is up 64.6% in 2026, up 3.6% in the previous five trading days and up 49.52% in the past year.

Currently, Halozyme Therapeutics, Inc.’s price-earnings ratio is 32.4. Halozyme Therapeutics, Inc.’s trailing 12-month revenue is $1.7 billion with a 24.9% net profit margin. Year-over-year quarterly sales growth most recently was 47.7%. Analysts expect adjusted earnings to reach $8.577 per share for the current fiscal year. Halozyme Therapeutics, Inc. does not currently pay a dividend.

How We Compare Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Arrowhead Pharmaceuticals, Inc.	ARWR	F
Halozyme Therapeutics, Inc.	HALO	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Arrowhead Pharmaceuticals, Inc. has a Growth Score of 14, which is Very Weak. Halozyme Therapeutics, Inc. has a Growth Score of 69, which is Strong.

The Growth Grade Winner: Halozyme Therapeutics, Inc.

As you can clearly see from the Growth Grade breakdown above, Halozyme Therapeutics, Inc. has a more attractive growth grade than Arrowhead Pharmaceuticals, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Halozyme Therapeutics, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Arrowhead Pharmaceuticals, Inc.	ARWR	A
Halozyme Therapeutics, Inc.	HALO	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Arrowhead Pharmaceuticals, Inc. has a Momentum Score of 95, which is Very Strong. Halozyme Therapeutics, Inc. has a Momentum Score of 90, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Arrowhead Pharmaceuticals, Inc.	ARWR	D
Halozyme Therapeutics, Inc.	HALO	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Arrowhead Pharmaceuticals, Inc. has a Earnings Estimate Score of 21, which is Negative. Halozyme Therapeutics, Inc. has a Earnings Estimate Score of 73, which is Positive.

The Earnings Estimate Revisions Grade Winner: Halozyme Therapeutics, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Halozyme Therapeutics, Inc. has a better Earnings Estimate Revisions Grade than Arrowhead Pharmaceuticals, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Halozyme Therapeutics, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. Grades

In addition to Momentum, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics or Inc. Stock?

Overall, Arrowhead Pharmaceuticals, Inc. stock has a Growth Score of 14, Momentum Score of 95 and Estimate Revisions Score of 21.

Halozyme Therapeutics, Inc. stock has a Growth Score of 69, Momentum Score of 90 and Estimate Revisions Score of 73.

Comparing Arrowhead Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.